M1 Kliniken AG announces financials for H1-2025

Berlin, 9. September 2025 – M1 Kliniken AG (ISIN: DE000A0STSQ8) successfully closed the first half of 2025, continuing its profitable growth trajectory. The significant improvement in results was mainly driven by consistently implemented efficiency measures and the targeted expansion of medical capacities.

Key Financials at a Glance

• Group revenue: +9.4% to EUR 183.5 million (H1 2024: EUR 167.7 million)
• EBITDA: +21% to EUR 20.5 million (H1 2024: EUR 17.0 million)
• EBIT: +24% to EUR 18.0 million (H1 2024: EUR 14.5 million)
• EBIT margin: 9.8% (H1 2024: 8.6%)
• EBT: +12% to EUR 16.9 million (H1 2024: EUR 15.0 million)
• Earnings per share: EUR 0.63 (H1 2024: EUR 0.53)

Beauty-Segment: Profitability Significantly Increased Once Again

• Revenue: +5.5% to EUR 51.2 million (H1 2024: EUR 48.6 million)
• EBIT: +48.9% to EUR 15.0 million (H1 2024: EUR 10.1 million)
• EBIT margin: 29.4% (H1 2024: 20.8%)

The Beauty segment remains the key growth driver of the Group. The positive development already evident in the first quarter continued in the second quarter of 2025. In the first half, the segment particularly benefited from efficiency gains through optimized processes and higher utilization of medical capacities. A targeted pricing strategy aimed at attracting new customer groups supported the expansion of market share – without compromising margin quality. The positioning as the leading provider of high-quality aesthetic medicine at the best price is being consistently pursued.

Double-Digit Revenue Growth in the Trading Segment

• Revenue: +11% to EUR 132.3 million (H1 2024: EUR 119.2 million)
• EBIT: -32.8% to EUR 2.9 million (H1 2024: EUR 4.4 million)

The Trading segment recorded a significant increase in revenue in the first half of 2025, while EBIT was below the previous year’s level.

Outlook

M1 Kliniken AG will continue its profitable growth trajectory by expanding its network of national and international clinics. For the full year 2025, revenue of between EUR 100 million and EUR 120 million is targeted in the Beauty segment. By 2029, this figure is expected to increase to between EUR 200 million and EUR 300 million – with a sustainable EBIT margin of at least 20%. The Group is consistently pursuing the goal of establishing M1 Med Beauty as the world’s leading brand for aesthetic medicine.

The potential sale of the HAEMATO AG trading segment as well as the continued interest of private equity investors in the Beauty segment remain ongoing